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The safety of using anti-VEGF remains a hot topic. There
are not many retinal specialists who have not “fought” at
one stage or another and tried to implement anti-VEGF into
their practice. Cost is a big issue. Nationally, some
countries have literally taken years to deliberate as to
whether ranibizumab is cost-effective. For example, in the
United Kingdom, the National Institute of Clinical Excellence
only came to its “final appraisal determination” in 2008 [1],
when the drug had been commercially available for some
years. Other countries have yet to decide. In China, the
Xinhau News Agency reported an incident where 61 out of
116 patients developed serious adverse reactions after
receiving bevacizumab injection in Shanghai No 1 People's
Hospital [2]. This reverberated around Asia, and raised again
the issue of who is liable when drugs are used off-label. The
uncertainty while we await the results of head-to-head
randomised trials between ranibizumab and bevacizumab
has led some national health services to choose pegaptanib as
the safest, affordable and approved first-line drug for the
treatment of macular degeneration.
In the October issue of the Archives of Ophthalmology,
Curtis et al. published an article on the risks of mortality,
myocardial infarction, bleeding, and stroke associated with
therapies for age-related macular degeneration (AMD) [3].
This is a retrospective study involving 146,942 patients
identified from the Centers for Medicare & Medicaid
Services for all Medicare beneficiaries from January 1
2004 through December 31 2007. Medicare-based studies
have a long track record of finding significant associations.
For example, in 1992 Javitt et al. studied 57,103 cases of
extracapsular cataract extraction, and identified that patients
who subsequently underwent capsulotomy had a 4-fold
increase in risk of developing retinal detachment. This was
the first time an incontrovertible link had been established
between yag laser capsulotomy and retinal detachment.
There is, therefore, a real strength in numbers. The weight
of evidence can definitively resolve some controversial
issues. Does the current study resolve once and for all the
safety issue with regard to anti-VEGF?
In this study, patients were divided into four groups,
depending on their initial treatment, namely photodynamic
therapy (PDT), pegaptanib, bevacizumab and ranibizumab.
Four adverse events were examined: all-cause mortality,
incident myocardial infarction, bleeding, and incident
stroke. Data from patients who received a different therapy
from the one they received initially were censored.
Naturally, the number of patients that received PDT and
pegaptanib declined throughout the period of the study.
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cumulative incidence of adverse event by treatment
group. There were statistically significant differences in
mortality; among beneficiaries who received pegaptanib,
4.8% died compared with 4.4% in the bevacizumab
group and 4.1% in the PDT and ranibizumab groups. The
cumulative incidence of myocardial infarction was
slightly higher in the PDT and pegaptanib groups than in
the bevacizumab and ranibizumab groups, but the overall P
value did not reach statistical significance. There was no
statistically significant relationship between treatment group
and bleeding events or stroke. Even after adjusting for
confounding factors such as age, gender, race/ethnicity and
co-morbidity, significant differences existed. The hazard of
mortality was significantly lower with ranibizumab use than
with PDT or pegaptanib use. The hazard of myocardial
infarction was significantly lower with ranibizumab use than
with PDT. There were no significant differences in the hazard
of mortality or myocardial infarction between bevacizumab
use and other treatments.
What is more interesting is the comparison between
bevacizumab and ranibizumab. A subgroup analysis was
made of 19,026 patients who received ranibizumab and
21,815 who received bevacizumab as first-line therapy. After
adjustment for baseline characteristics and co-morbid con-
ditions, the hazards of mortality and stroke (hazard ratio of
0.86 and 0.78) were significantly lower with ranibizumab
therapy than with bevacizumab therapy. The authors thought
that patients with higher socioeconomic status may have been
more likely to receive ranibizumab vs bevacizumab, so the
primary analysis may have been subject to selection bias.
Therefore, in a secondary analysis, the study population was
limited to patients who received ranibizumab or bevacizumab
in medical practices that basically used either bevacizumab or
ranibizumab exclusively during the third or fourth quarter of
2006. The results then show no difference.
There are always limitations with this type of study. The
large number involved means that many significant associa-
tions can be discovered. However, one should appreciate the
result merely points to association and not necessary
causation. We do not know if other factors such as
socioeconomic status caused bias. It is always easy to say
that a randomised control trial will resolve the matter
definitively. The authors pointed out, “The National Eye
Institute–sponsored comparative trial of the efficacy of
ranibizumab and bevacizumab will randomly assign 1,200
patients with newly diagnosed age-related macular degener-
ation to one of four treatment groups (two bevacizumab
regimens and two ranibizumab regimens). Given the baseline
risks of thromboembolic events in this population, the sample
sizeneededtodetectevena50%relativeincreaseinrisk(from
2.0% to 3.0%) would be at least an order of magnitude larger
than the trial protocol dictates. As designed, the trial will not
adequately assess the relative safety of the two therapies.”
The take-home measure for me personally is that the risk
overall with anti-VEGF use is small, and comparable with
that for PDT. Within the limitations of the study, it is not
unreasonable to think that the selective anti-VEGF is not
superior in its safety profile compared to pan anti-VEGF
agents. The small difference between bevacizumab and
ranibizumab might well be spurious, but will no doubt fuel
more discussions.
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